Location:Home > Xiangya News > News

Team of Associate Professor Huang Jin from the Department of Oncology published a research paper in Gut

2021-07-03

Recently, Associate Professor Huang Jin, M.D. from the Department of Oncology, Xiangya Hospital, Central South University published an original article titled CDK1/2/5inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer in Gut (IF23.059), the official journal of the British Society of Gastroenterology. Dr. Huang is the first author. This research provides a new way for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC) through the use of cyclin-dependent kinase (CDK) 1/2/5 inhibitor dinaciclib to overcome IFNG-mediated adaptive immune resistance.


Over the past decades, the survival rate of patients with PDAC has not been improved despite numerous clinical trials. To be specific, adaptive immune resistance mediated by the cytokine interferon gamma (IFNG) still constitutes a major problem in cancer immunotherapy, and dysregulation of the CDK family plays a complex role in tumor immune regulation. In order to find ways to overcome IFNG-mediated adaptive immune resistance in pancreatic ductal adenocarcinoma, Dr. Huang conducted an in-depth research and analysis by screening and identifying a CDK1/2/5 inhibitor, namely, dinaciclib, in the protein kinase inhibitor library. According to the research results, dinaciclib triggers histone-dependent immunogenic cell death, which promotes effective anti-tumor immunity. The mechanism turns an immunologically “cold” tumor microenvironment into a “hot”one in mouse pancreatic tumor models. The research finding has facilitated the study of tumor immune escape mechanism and the development of pancreatic cancer treatment model, which provides new strategies for the precise treatment of this kind of diseases.

Dr. Huang focuses on the integrated prevention and treatment of gastrointestinal tumors. She specializes in the medical treatment of oral cancer and malignant gastrointestinal tumors, as well as the targeted therapies and immunotherapy of various malignant tumors. She also studies the pharmacoeconomics of immunotherapy for malignant tumors and the immune mechanism of gastrointestinal tumors in terms of basic research. Dr. Huang has undertaken several national and Hunan provincial research projects and published 19 high-quality SCI papers.

  
Link to the original text:
https://gut.bmj.com/content/70/5/890.long

Xiangya Hospital Central South University
All Rights Reserved.